

REGISTERED No. M - 302
L-7646

The Gazette  **of Pakistan**

**EXTRAORDINARY
PUBLISHED BY AUTHORITY**

ISLAMABAD, TUESDAY, AUGUST 6, 2013

PART II

Statutory Notifications (S.R.O.)

GOVERNMENT OF PAKISTAN

DRUG REGULATORY AUTHORITY OF PAKISTAN
(National Health Services, Regulations and Coordination Division)

NOTIFICATION

Islamabad, the 5th August, 2013

S.R.O. 707 (I)/2013.—In exercise of the powers conferred by section 10 and sub-section (3) of section 12 of the Drugs Act, 1976 (XXXI of 1976), read with clause (a) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) and in supersession of its Notification No. S.R.O. 41(I)/2013, dated the 18th January, 2013, the Drug Regulatory Authority of Pakistan, with the approval of the Federal Government, is pleased to constitute a Drug Pricing Committee comprising of the following, namely:—

(2259)

Price : Rs. 2.00

[1141 (2013)/Ex. Gaz.]

S.No.	Composition	Status
(1)	(2)	(3)
1.	Director Costing and Pricing, Drug Regulatory Authority of Pakistan.	<i>Chairperson</i>
2.	Secretaries, Department of Health from each Province or their nominees not below the rank of an officer of BPS-19.	<i>Members</i>
3.	Chief Cost Accounts Officer or Cost Accountant, Ministry of Finance, Government of Pakistan.	<i>Member</i>
4.	Deputy Director General (Pricing)/Deputy Drugs Controller (Pricing), Drug Regulatory Authority of Pakistan.	<i>Secretary</i>
5.	Representative of Pakistan Medical Association.	<i>Co-opted Member</i>
6.	Representative of Consumer Rights Commission of Pakistan.	<i>Co-opted Member</i>
7.	Representative of Pharma Bureau (Overseas Investors Chamber of Commerce and Industry).	<i>Observer</i>
8.	Representative of Pakistan Pharmaceutical Manufacturers Association.	<i>Observer</i>

2. The terms of reference of the said committee shall be as under, namely:—

- (i) to fix and review the maximum retail price at which a drug or biological is to be sold subject to approval by the Federal Government;
- (ii) to advise the Federal Government on matters related to drugs pricing;
- (iii) to monitor availability of drugs at the approved prices, throughout the country and to give such directions to the Provincial Governments and the Federal Inspectors of Drugs, in this regard, as it may deem fit; and
- (iv) to issue orders as to the actions to be taken in respect of any contravention of Drugs Act, 1976 (XXXI of 1976) and the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) regarding pricing matters referred to it by the Federal Inspector;

3. The observers on the committee shall not have a right to vote in the decision making.

[No. F. 11-11/2012-DDC (P).]

MUHAMMAD ARSHAD KHAN,
Director Legal Affairs.